# Glioblastoma Multiforme FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/glioblastoma-multiforme

> 2 upcoming FDA catalysts in glioblastoma Multiforme: nano2tm (NUOX) on Jun to Sep 2027 (topline data readout); nano2tm (NUOX) on June 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2025 | [ICT-107 primary completion](https://sec-api.dev/pdufa/ict-107) | DTIL | Glioblastoma Multiforme | delayed | "NCT02546102 (Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma): Overall Status SUSPENDED; Phase PHASE3; Primary Completion 2025-12 (ESTIMATED); Lead Sponsor Precision Life Sciences Group." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02546102)) |
| Jun to Sep 2027 | [Nano2tm topline data readout](https://sec-api.dev/pdufa/nano2tm) | NUOX | Glioblastoma Multiforme | scheduled | "NCT03862430 (A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor NuvOx LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03862430)) |
| June 2027 | [Nano2tm primary completion](https://sec-api.dev/pdufa/nano2tm) | NUOX | Glioblastoma Multiforme | scheduled | "NCT03862430 (A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor NuvOx LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03862430)) |

## Drugs

- [ICT-107](https://sec-api.dev/pdufa/ict-107) (DTIL)
- [Nano2tm](https://sec-api.dev/pdufa/nano2tm) (NUOX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/glioblastoma-multiforme.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Glioblastoma Multiforme FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/glioblastoma-multiforme

```bibtex
@misc{secapidev_indications_glioblastoma_multiforme_20261116,
  title        = {Glioblastoma Multiforme FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/glioblastoma-multiforme}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_glioblastoma_multiforme_20261116","title":"Glioblastoma Multiforme FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/glioblastoma-multiforme","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
